化学療法剤の適切な使い方について

Similar documents
分子標的薬アプデート 2018

437“ƒ

untitled

untitled

< >

日本皮膚科学会雑誌第122巻第2号


untitled

PDF変換用(報告書)帯広市新エネルギービジョ

日本皮膚科学会第121巻第9号

E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL

untitled

untitled





物理化学I-第12回(13).ppt

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

Microsoft Word - 海岸紹介new.doc

取扱説明書 [F-05E]

スライド 1

空き容量一覧表(154kV以上)

Atlas_j060419

2/8 一次二次当該 42 AX 変圧器 なし 43 AY 変圧器 なし 44 BA 変圧器 なし 45 BB 変圧器 なし 46 BC 変圧器 なし


終末期の呼吸困難症状への対応*松坂最終修正


a s d

a s d

所得税の確定申告の手引き

日本皮膚科学会雑誌第121巻第11号

Microsoft Word - ゴールドコーストマラソン2014.docx

CRA3689A

Rinku General Medical Center


<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>

CAR-T実施

32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ

1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です


DM

<90CE90EC88E290D55F955C8E862E656336>

The Heart Healthy Tocotrienol Complex Tocomin SupraBio


/ 30 / - 2 -

10K1A NASA () SPACE ATLAS Freedom H2A NASA 1

untitled

卵巣癌の治療

1

1/68 A. 電気所 ( 発電所, 変電所, 配電塔 ) における変圧器の空き容量一覧 平成 31 年 3 月 6 日現在 < 留意事項 > (1) 空容量は目安であり 系統接続の前には 接続検討のお申込みによる詳細検討が必要となります その結果 空容量が変更となる場合があります (2) 特に記載


取扱説明書

橡

SD SD SD

防災業務計画


ver11_B06-B07_kyozaisakusei.indd

pdf

近畿中国四国農業研究センター研究報告 第7号

肺癌第50巻第4号

UX-V503CL/UX-V503CW

42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =

ライフサイエンス関連 コラーゲン・ゼラチン製品案内 

JSP58-program


, ,

【知事入れ版】270804_鳥取県人口ビジョン素案

表1.eps

O-1 O-2 O-3 O-4 O-5 O-6


かんたん操作ガイド[arrows M02]

かんたん操作ガイド[arrows RM02]



かんたん操作ガイド[arrows M03]

JA2008

東海道新幹線でDS



1

Juntendo Medical Journal

(1) (2) (1) (2) (1) Seg (2) Seg (3) Seg (4) Seg (1) (2) (3) ( ) (1) (PCA)...12


表紙_02




野岩鉄道の旅

中期経営計画 「NEXTAGE‐05」説明会

1

慢性膵炎

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate


untitled

 

土砂流入対策実施計画〔久著呂川〕

36 th IChO : - 3 ( ) , G O O D L U C K final 1

2001 Mg-Zn-Y LPSO(Long Period Stacking Order) Mg,,,. LPSO ( ), Mg, Zn,Y. Mg Zn, Y fcc( ) L1 2. LPSO Mg,., Mg L1 2, Zn,Y,, Y.,, Zn, Y Mg. Zn,Y., 926, 1

untitled

Transcription:

1 2 3 4

5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology 5th Ed. Devita, 1997

9 Rassnick KM, Vet Comp Oncol, 2010 Vaughan A, JVIM, 2007 Frimberger AE, JVIM, 2006 10 IIIVn= 66 L-CHOP-CCNU-MOPP p= 0.05 L-CHOP Rassnick KM, Vet Comp Oncol, 2010 11 IIIVn= 62 34 Vaughan A, JVIM, 2007 12 IIIVn= 28 VELCAP p= 0.027 Frimberger AE, JVIM, 2006

13 14 CCNU (70mg/m 2 ) CCNU(60mg/m 2 ) CCNU (60mg/m 2 ) CCNU (60mg/m 2 ) SD PR CR Grade4 Seg= 37 Grade4 Seg= 34 Grade4 Seg= 251 Grade4 Seg= 169 821kg 16

17 Ogilvie GK, JAVMA, 1993 18 19!20 PDGFR= VEGFR= PDGF PDGF & PDGFR-β binding VEGF PDGFR-β トセラニブ VEGF & VEGFR-2 binding VEGFR-2 トセラニブ

21 London CA, Vet Compar Oncol, 2011 22 n= 85 % n=32 n=23 n=15 n=8 n=7 London CA, Vet Compar Oncol, 2011 23 n= 85 London CA, Vet Compar Oncol, 2011 24

25!26 27 Samm, 2010 Phillips, 2009 Kow, 2008-13295CI: -211 to -52) Boerman I, BMC Vet Res, 2012 28

!29!30 286 Give Up? Yeah, used to be...!32 286

!33 363!34 412!35 440!36 475

!37 501!38 574 39 40 Lee KW et al., Cancer, 2003

41 Lee KW et al., Cancer, 2003 42 43 44

45 46 n CR CR 9 50% 5 Jeglum KA, JAVMA, 1987 28 32% 7.1 Mahony OM, JAVMA, 1994 50-7.6 Vail DM, JVIM, 1998 21 38% 4.7 Zwahlen CH, JAVMA, 1998 11 64% 8.2 Teske E, JVIM, 2002 10 40% 34.8 Limmer S, VCO, 2014 75 30% 1.7PFI Collette SA, VCO, 2015 * CHOP 47!48 n=20 Gouldin ED, VCO, 2015

49 Rassnick KM, JAVMA, 2001 50 Dank G, Vet Comp Oncol, 2012 51 % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J. 2014 52 % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J. 2014

53 % 1. Moore AS, J Vet Intern Med. 1990, 2. Chun R, J Am Vet Med Assoc. 1996, 3. Knapp DW, Cancer Chemother Pharmacol. 2000, 4. Chun R, Vet Intern Med. 1997, 5. Knapp DW, J Vet Intern Med. 1994, 6. Mutsaers AJ, J Vet Intern Med. 2003, 7. Knapp DW, J Vet Intern Med. 2013, 9. Arnold EJ, J Vet Intern Med. 2011, 12. Robat C, J Small Anim Pract. 2013, 13. Mohammed SI, Cancer Res. 2002, 14. Mohammed SI, Mol Cancer Ther. 2003, 15. Boria PA, Vet Comp Oncol. 2005, 16. Greene SN, J Am Vet Med Assoc. 2007, 18. Marconato L, J Am Vet Med Assoc. 2011, 19. Kaye ME, Vet Comp Oncol. 2013, 20. Schrempp DR, J Am Vet Med Assoc. 2013, 21. Henry CJ, Clin Cancer Res. 2003, 22. Knapp DW, Small Animal Clinical Oncology (5 th ed), 2013, 23. Perazella MA, Semin Nephrol. 2010, 24. Rao P, J Pharm Pharm Sci. 2008, 25. Allstadt SD, J Vet Intern Med 2015, 26. Knapp DW, ILAR J. 2014 55 56

!57!58 60

61 Berg J, Cancer, 1997 62 n= 102) 2 10 15-20mg/m 2 IV 60mg/m 2 ) IV 23 x 3 Berg J, Cancer, 1997 63 n vs. P<0.000012 vs. 10p=0.727 Berg J, Cancer, 1997 64 Berg J, Cancer, 1997

65 Berg J, Cancer, 1997 66 67 adriamycin@mac.com